After disclosing that the Food and Drug Administration has accepted the company's application to review its lead product candidate for approval, shares of Global Blood Therapeutics (NASDAQ: GBT) rallied 10.9% on Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,